Monday, February 16, 2026
28
C
Bengaluru
Hot topics
National Seminar on UCPMP
The seminar will help companies especially Product Management Teams and Sales Teams to understand their changing roles due to UCPMP. It will also bring clarity on strategies and promotional inputs including CME's, sampling, gifts etc.
Digital Transformation and the World of Pharma
A big myth about digital transformation is that it...
You can Lead People
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, Soham Wagh and Amit Jain
Role of AI Across Pharma Industry
Introduction
Artificial intelligence (AI) is increasingly pivotal in driving innovation...
The Evolving Role of HR in Pharma: Why Non-Pharma Backgrounds are Raising the Game
The pharmaceutical sector—high-stakes, heavily regulated, and innovation-driven—has historically preferred...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Hot topics
An Invitation from the Editor
FFE and BrandStorm 2016 Agenda inside. Articles by Raja Reddy, K. Hariram, Amit Jain, and Vivek Hattangadi.
Will Omicron Wave be a Repeat Rx for Indian Pharma?
How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
Track and Trace: Indian Pharma – Current and Future Applicability
Pharmaceutical companies must contend with challenges from supply chain lapses (theft, diversion, S.O.P. deviations, product recalls, reverse logistics etc.) counterfeiting and stringent regulations. These challenges get compounded when dealing across the states and country business operations, besides that not only impact tangible profits but also the intangible brand credibility. In this context, there is also a credible increase in public awareness about the genuineness of medicine (in particular medicine that require cold chain) and their predictability of clinical outcomes.
Providing visibility and full traceability becomes a paramount importance to both the Industry and the Govt. – A fool proof solution not only brings transparency in the system, but can also be a key differentiator, and undoubtedly can create immense opportunities for a competitive advantage.
Torrent Pharma–JB Chemicals Acquisition Report
Summary
Torrent Pharmaceuticals (TRP) has signed definitive agreements...
Creating A Winning Sales Organisation – Workshop Announcement
MedicinMan catches up with Deep Bhandari - Advisor at UCB where he...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?
Transparency, Trust, and the Problem of “Invisible Evidence” in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
India’s caesarean section debate is drifting toward polarisation.
On one...
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
In big pharma, leadership changes are rarely impulsive. They...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Newsletter
Get important news delivered directly to your inbox and stay connected!